CJC + Ipamorelin vs CJC-1295 No DAC & Ipamorelin

CJC + Ipamorelin vs CJC-1295 No DAC & Ipamorelin CJC + Ipamorelin typically refers to CJC-1295 no DAC paired with Ipamorelin — same peptides, different names. We explain the naming confusion and what A researcher orders a vial labeled 'CJC + Ipamorelin' from one supplier and 'CJC-1295 no DAC & Ipamorelin' from another. Then spends an hour online trying to confirm they ordered the same thing. That confusion isn't your fault. The peptide research space has no standardized naming convention, so suppliers use shorthand that assumes you already know what CJC means. You don't get a product insert explaining that 'CJC' is vendor shorthand for 'CJC-1295 without Drug Affinity Complex modification.' Our team has worked with peptide researchers navigating this exact labeling gap for years. The compounds are identical. The names are just inconsistently shortened. What is CJC + Ipamorelin same as CJC-1295 no DAC & Ipamorelin? Yes, 'CJC + Ipamorelin' and 'CJC-1295 no DAC & Ipamorelin' refer to the same peptide combination. CJC is vendor shorthand for CJC-1295 no DAC (modified growth hormone-releasing hormone), paired with Ipamorelin (a selective ghrelin receptor agonist). The two peptides synergistically stimulate pulsatile growth hormone release. CJC-1295 no DAC extends the amplitude of each pulse, while Ipamorelin triggers the pulse itself without elevating cortisol or prolactin. The naming inconsistency exists because 'CJC-1295 no DAC' is technically a misnomer that stuck. The original CJC-1295 (with DAC) and the modified growth hormone-releasing hormone analog most researchers use (no DAC) are structurally different. One has a half-life of 8 days, the other approximately 30 minutes. When suppliers write 'CJC,' they mean the short-acting no-DAC version unless explicitly stated otherwise. This article covers why the naming split happened, what the peptides actually do at the receptor level, and how to verify you're getting the compound you intended when labels don't match across sources. The confusion starts with CJC-1295 itself. In 2005, a research team synthesized a modified growth hormone-releasing hormone (GHRH) analog with an added Drug Affinity Complex (DAC). A chemical modification that extended the peptide's half-life from under 10 minutes to approximately 6–8 days. That compound was named CJC-1295. The modification worked: weekly dosing became viable, and the peptide showed sustained elevation of growth hormone and IGF-1 levels in clinical trials. But researchers also wanted the short-acting version. The same peptide without the DAC modification. That compound (tetrasubstituted GHRH 1–29) became known as 'CJC-1295 no DAC,' even though it's technically not CJC-1295 at all. It's the base analog before DAC was added. The name stuck because suppliers needed to differentiate the two, and 'CJC-1295 no DAC' was clearer than introducing a completely new name. Over time, vendors shortened it further to just 'CJC' or 'modified GRF 1–29.' When paired with Ipamorelin, most suppliers write 'CJC + Ipamorelin' or 'CJC/Ipamorelin blend.' The assumption: if you're ordering a blend, you want the short-acting version (no DAC). Because pairing the long-acting DAC version with a short-acting secretagogue like Ipamorelin creates mismatched pharmacokinetics that negate the synergy. CJC-1295 no DAC and Ipamorelin target different receptors in the pituitary gland to amplify endogenous growth hormone secretion. CJC-1295 no DAC is a GHRH analog. It binds to growth hormone-releasing hormone receptors on somatotroph cells, triggering cyclic AMP signaling and increasing intracellular calcium, which drives growth hormone synthesis and secretion. Its half-life of approximately 30 minutes makes it ideal for pulsatile dosing that mimics the body's natural circadian GH rhythm. Ipamorelin is a ghrelin receptor agonist. Specifically, it binds to the GHS-R1a receptor (growth hormone secretagogue receptor) without activating receptors that elevate cortisol (ACTH) or prolactin. This selectivity is what differentiates Ipamorelin from earlier secretagogues like GHRP-2 or GHRP-6, which caused hunger spikes and cortisol elevation. Ipamorelin's binding affinity produces a sharp, controlled GH pulse without downstream hormonal disruption. When dosed together, CJC-1295 no DAC extends the amplitude of the GH pulse triggered by Ipamorelin. Research published in the Journal of Clinical Endocrinology & Metabolism demonstrated that combining GHRH analogs with ghrelin mimetics produces GH release 3–5 times greater than either peptide alone. The synergy comes from dual-pathway activation: GHRH receptors drive synthesis, ghrelin receptors drive release. Our team has found that researchers using the combination report more consistent IGF-1 elevation compared to single-peptide protocols. If a supplier labels a product 'CJC + Ipamorelin,' you need to verify it's the no-DAC version before reconstituting. The simplest check: ask for the Certificate of Analysis (CoA) and look for the peptide sequence. CJC-1295 no DAC (modified GRF 1–29) has 29 amino acids with four specific substitutions at positions 2, 8, 15, and 27. These substitutions prevent enzymatic degradation that would otherwise break the peptide down in under 7 minutes. If the CoA lists the full sequence or molecular weight (3367.9 Da for the acetate salt), it's the no-DAC version. CJC-1295 with DAC has a molecular weight of approximately 3647 Da due to the maleimidoproprionic acid linker attached at lysine-12. If you see that MW on the CoA, you've received the long-acting version. Which is not what most researchers want in a blend with Ipamorelin. The mismatch creates pharmacokinetic inefficiency: Ipamorelin clears in 2–3 hours, while DAC-modified CJC remains active for days, meaning the synergistic pulse effect only occurs during the first few hours post-injection. At Real Peptides, every batch of our CJC1295 Ipamorelin 5MG 5MG blend is labeled with the full peptide names and third-party verified CoA available on request. No ambiguity about which CJC variant you're receiving. Peptide Structure Modified GRF 1–29 (29 amino acids, 4 substitutions) + Ipamorelin pentapeptide Identical. Modified GRF 1–29 + Ipamorelin CJC-1295 with maleimidoproprionic acid linker + Ipamorelin Same peptides, different shorthand Half-Life ~30 minutes (CJC no DAC) + ~2 hours (Ipamorelin) ~30 minutes + ~2 hours ~6–8 days (CJC with DAC) + ~2 hours (Ipamorelin) No-DAC version matches Ipamorelin kinetics Dosing Frequency Daily or twice-daily pulsatile dosing Weekly CJC + daily Ipamorelin (pharmacokinetic mismatch) Pulsatile protocols require no-DAC Synergistic Effect Full synergy. Both peptides clear within hours, pulse effect intact Full synergy. Matched kinetics Partial synergy. Only first 2–3 hours post-dose aligned Matched half-lives maximize GH amplitude Typical Research Dose Range 100–200 mcg CJC + 200–300 mcg Ipamorelin per dose 1–2 mg CJC weekly + 200–300 mcg Ipamorelin daily Dose ranges identical for no-DAC blends CJC + Ipamorelin and CJC-1295 no DAC & Ipamorelin refer to the same peptide combination. 'CJC' is vendor shorthand for the modified GHRH analog without Drug Affinity Complex modification. CJC-1295 no DAC has a half-life of approximately 30 minutes, making it ideal for pulsatile dosing protocols that mimic natural growth hormone secretion patterns. Ipamorelin selectively activates GHS-R1a receptors without elevating cortisol or prolactin, producing clean GH pulses with minimal downstream hormonal interference. When combined, the two peptides produce 3–5 times greater GH release than either compound alone due to dual-pathway activation of GHRH and ghrelin receptors. Certificate of Analysis verification is essential. Molecular weight of 3367.9 Da confirms CJC-1295 no DAC, while 3647 Da indicates the long-acting DAC version that doesn't pair well with Ipamorelin. Request the CoA and check the molecular weight. If the supplier lists CJC-1295 without clarifying 'no DAC' or 'with DAC,' assume ambiguity and verify before use. A reputable supplier provides the full peptide sequence or MW on request. If they refuse or claim proprietary formulation, source elsewhere. The pharmacokinetic mismatch between CJC-1295 with DAC (half-life 6–8 days) and Ipamorelin (half-life 2–3 hours) eliminates the pulsatile synergy that makes the combination valuable. You can still use it, but not in the same protocol. CJC-1295 with DAC is dosed weekly at 1–2 mg to maintain elevated baseline GH and IGF-1 levels. It's a sustained-release approach, not a pulsatile one. Pairing it with daily Ipamorelin won't harm anything, but the synergy only occurs for the first 2–3 hours after each Ipamorelin dose. Most researchers using the DAC version skip Ipamorelin entirely and rely on the long half-life for continuous GH elevation. Cloudiness in reconstituted CJC + Ipamorelin indicates aggregation. Peptide molecules clumping due to incorrect pH, temperature shock, or contamination during reconstitution. Discard the vial. Aggregated peptides have unpredictable bioavailability and may contain particulates that shouldn't be injected subcutaneously. The solution should be clear and colorless. If cloudiness appears immediately after adding bacteriostatic water, the lyophilized powder may have degraded during storage. Temperature excursions above 8°C during shipping cause irreversible denaturation. Here's the honest answer: the peptide research industry has no standardized nomenclature, and suppliers shorten names for convenience without considering that new researchers don't know the backstory. When you see 'CJC,' you're supposed to already know it means 'CJC-1295 no DAC'. But nowhere on the label does it say that. The assumption is you've done enough research to understand the difference, which is backwards. A supplier selling research-grade compounds should label them with precision, not shorthand. The naming confusion isn't accidental. It's inherited from the early 2000s when CJC-1295 with DAC was the only version available. When the no-DAC variant became the standard for pulsatile protocols, suppliers kept 'CJC-1295' in the name to maintain brand recognition, then added 'no DAC' as a modifier. Over time, 'no DAC' got dropped from labels entirely because most researchers ordering blends want the short-acting version by default. The result: a compound that's technically not CJC-1295 gets sold under a name that implies it is. If you're ordering peptides for the first time, verify the CoA every time. Don't assume 'CJC' means what you think it means. Whether labeled 'CJC + Ipamorelin' or 'CJC-1295 no DAC & Ipamorelin,' reconstitution and storage protocols are identical. Store lyophilized powder at −20°C before reconstitution. Peptides are stable at this temperature for 12–24 months when protected from light and moisture. Once reconstituted with bacteriostatic water (0.9% benzyl alcohol), refrigerate at 2–8°C and use within 28 days. Any temperature excursion above 8°C accelerates oxidation of methionine residues at positions 27 and 29, which reduces receptor binding affinity. Reconstitute by adding bacteriostatic water slowly down the inside wall of the vial. Never inject directly onto the lyophilized cake, as the mechanical force can shear peptide bonds. Swirl gently to dissolve; do not shake. Shaking introduces air bubbles and creates shear stress that denatures tertiary structure. The reconstituted solution should be clear and free of particulates. If you see visible aggregates or cloudiness, discard the vial. Aggregated peptides have unpredictable bioavailability and may contain fragments that trigger immune responses. Our experience with researchers in this space: the most common error isn't contamination during reconstitution. It's failing to pre-chill the bacteriostatic water to 2–8°C before adding it to the peptide. Room-temperature water creates a brief thermal gradient inside the vial that accelerates degradation during the dissolution phase. The information in this article is for educational purposes. Peptide selection, dosing, and reconstitution decisions should be made in consultation with qualified research protocols and institutional guidelines. If the label says 'CJC + Ipamorelin' and the CoA confirms modified GRF 1–29 without DAC modification, you have exactly what you ordered. The name is shorthand. The peptide is the same. Yes. ‘CJC + Ipamorelin’ is vendor shorthand for ‘CJC-1295 no DAC & Ipamorelin’ — the peptides are identical. Suppliers shorten ‘CJC-1295 no DAC’ to ‘CJC’ because the short-acting no-DAC version is the standard formulation used in peptide blends. The full name is ‘modified growth hormone-releasing hormone (1–29) paired with Ipamorelin,’ but most labels use the abbreviated form. Check the Certificate of Analysis (CoA) for molecular weight. CJC-1295 no DAC has a molecular weight of 3367.9 Da, while CJC-1295 with DAC is approximately 3647 Da due to the added maleimidoproprionic acid linker. If the CoA lists the peptide sequence, look for 29 amino acids with substitutions at positions 2, 8, 15, and 27 — that’s the no-DAC version. Reputable suppliers provide CoAs on request; if a supplier refuses, source elsewhere. You can, but the synergy is reduced. CJC-1295 with DAC has a half-life of 6–8 days, while Ipamorelin clears in 2–3 hours — the pulsatile GH release effect only aligns during the first few hours post-dose. Most researchers use CJC-1295 with DAC as a standalone weekly dose for sustained GH elevation, not in combination with short-acting secretagogues. If you want the full synergistic pulse effect, use the no-DAC version. They are the same peptide. ‘Modified GRF 1–29’ is the chemical name for the 29-amino-acid growth hormone-releasing hormone analog with four substitutions that extend its half-life to approximately 30 minutes. ‘CJC-1295 no DAC’ is the vendor name that stuck after researchers wanted to differentiate it from the original CJC-1295 with Drug Affinity Complex modification. Both names refer to tetrasubstituted GHRH (1–29). Research published in the Journal of Clinical Endocrinology & Metabolism found that combining GHRH analogs with ghrelin receptor agonists produces growth hormone release 3–5 times greater than either peptide alone. The synergy comes from dual-pathway activation: GHRH receptors drive GH synthesis, while ghrelin receptors trigger release. The combined effect produces higher-amplitude GH pulses without elevating cortisol or prolactin. The peptides will degrade within 24–48 hours. Bacteriostatic water contains 0.9% benzyl alcohol, which inhibits bacterial growth and extends the solution’s sterility and stability to 28 days when refrigerated. Regular sterile water lacks this preservative, so any bacteria introduced during reconstitution or repeated draws will proliferate rapidly. If you accidentally used sterile water, transfer the solution to a sterile vial, refrigerate immediately, and use within 24 hours. Labeling space constraints and industry shorthand. Suppliers assume researchers already know ‘CJC’ refers to CJC-1295 no DAC, so they shorten the label for simplicity. The practice is inconsistent across vendors — some write ‘CJC + Ipamorelin,’ others write ‘CJC-1295/Ipamorelin,’ and some use ‘modified GRF + Ipa.’ All refer to the same peptide combination unless the CoA specifies the DAC version. No. Reconstituted p